Oncosil Medical (ASX:OSL)
ASX announcement history & article coverage
Transparent by design.
Announcments by Oncosil Medical (ASX:OSL) are listed here, whether we covered it or not. Where we've written an article, you'll see it linked directly. Where we haven't, the filing is still shown so nothing is hidden from view. If you think a particular announcement deserved editorial coverage and was overlooked, you can flag it for review and our team will take a look.
OncoSil Medical Completes Manufacturing Validation
OncoSil Medical Completes Manufacturing Validation and Establishes Scalable Australian Production
TRIPP-FFX Results Presented at ESMO GI 2026
OncoSil Medical Files for FDA Approval
OncoSil Medical files FDA HDE application for OncoSil™ device to treat distal cholangiocarcinoma
OncoSil Selected for Major European Pancreatic Cancer Study
OncoSil Medical joins major European pancreatic cancer consortium with cost-efficient PULSE trial
TRIPP-FFX Abstract Published on ESMO GI 2026 Website
Notice under ASX Listing Rule 3.10A
Publication verifies OncoSil strong localisation in pancreas
OncoSil Medical Launches Investor Hub
Change in substantial shareholding from AEF
TRIPP FFX accepted for oral presentation at ESMO GI 2026
US FDA HDE and TRIPP-FFX Study Presentation
OncoSil Medical Nears FDA Approval and Reports Positive TRIPP-FFX Trial Results
OncoSil progresses HDE with US FDA
OncoSil Medical Advances to Final FDA Review Stage for HDE Approval of OncoSil™ Device
TRIPP-FFX Clinical Trial Meets Co-Primary Endpoints
Trading Halt
TRIPP FFX Clinical Trial to Report Results in June
Key New Ethics Approval for Italian Patient Registry
OncoSil Medical Secures Key Ethics Approval in Italy to Expand OncoSil™ Device Access and Commercial Rollout
Application for quotation of securities - OSL
Notification regarding unquoted securities - OSL
Appointment of Company Secretary
New Clinical Evidence for OncoSil Device Presented at ASCO
OncoSil Medical Receives TGA Approval in Australia
OncoSil Medical Secures TGA Approval for Pancreatic Cancer Device in Australia
OSPREY Interim Results Presented at ESGE Days 2026
OncoSil Medical reports positive interim OSPREY Registry results showing safety and efficacy in pancreatic cancer treatment
Quarterly Activities/Appendix 4C Cash Flow Report
OncoSil Medical Q3 FY26 dose sales surge 60%, key trials advance, new manufacturing facility on track
